Health
Study examines efficacy of Pfizer-BioNTech mRNA COVID-19 vaccine across demographic groups – News-Medical.Net
A new study examines data from Israel’s vaccination campaign to assess the efficacy of the Pfizer-BioNTech mRNA vaccine across different demographics.
Scientists across the world are racing against time to develop effective vaccines for severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) to contain the current coronavirus disease 2019 (COVID-19) pandemic. The phase III trial of the mRNA-based BNT162b2 COVID-19 vaccine showed 95% efficacy in preventing SARS-COV-2 infection. In this randomized placebo-controlled trial, the vaccine was found to be effective 12 days following the first dose. Despite several advantages of a controlled trial,…
-
Business23 hours agoWhat Warren Buffett’s farewell letter means for Berkshire Hathaway investors
-
General23 hours agoEnvironment Bill passes Senate as Greens cut deal with Labor
-
General7 hours agoQantas terminal at Melbourne Airport evacuated and flights delayed due to fire
-
General22 hours agoCalls for states to change alcohol laws ahead of women’s ministers meeting